肝细胞癌：发病机制、检测与治疗的新进展
Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment.
作者信息
Martínez-Chantar Maria L, Avila Matias A, Lu Shelly C
机构信息
CIC bioGUNE, Bizkaia Technology Park, 48160 Derio, Spain.
National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), 28029 Madrid, Spain.
出版信息
Cancers (Basel). 2020 Sep 23;12(10):2729. doi: 10.3390/cancers12102729.
Abstract
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the second most common cause of cancer mortality worldwide [...].
摘要
肝细胞癌（HCC）是最常见的原发性肝癌，也是全球癌症死亡的第二大常见原因[……]
相似文献
1
Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment.
Cancers (Basel). 2020 Sep 23;12(10):2729. doi: 10.3390/cancers12102729.
2
Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy.
Vaccines (Basel). 2023 Mar 8;11(3):614. doi: 10.3390/vaccines11030614.
3
Advances in novel systemic therapies for advanced hepatocellular carcinoma.
Future Med Chem. 2022 Oct;14(20):1455-1470. doi: 10.4155/fmc-2022-0045. Epub 2022 Aug 23.
4
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
J Biomed Sci. 2022 Jan 21;29(1):5. doi: 10.1186/s12929-022-00788-0.
5
Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.
Invest New Drugs. 2023 Jun;41(3):532-538. doi: 10.1007/s10637-023-01363-6. Epub 2023 Apr 26.
6
Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
J Formos Med Assoc. 2022 Aug;121(8):1371-1383. doi: 10.1016/j.jfma.2022.03.017. Epub 2022 Apr 7.
7
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma.
Expert Opin Emerg Drugs. 2021 Mar;26(1):39-52. doi: 10.1080/14728214.2021.1902503. Epub 2021 Mar 19.
8
Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
Surg Oncol. 2022 Jun;42:101748. doi: 10.1016/j.suronc.2022.101748. Epub 2022 Apr 1.
9
Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
Biomedicines. 2022 Dec 9;10(12):3202. doi: 10.3390/biomedicines10123202.
10
Immunotherapy Updates in Advanced Hepatocellular Carcinoma.
Cancers (Basel). 2021 Apr 30;13(9):2164. doi: 10.3390/cancers13092164.
引用本文的文献
1
Mechanisms underlying hepatocellular carcinoma progression through N6-methyladenosine modifications of long non-coding RNA.
World J Gastroenterol. 2025 Jun 7;31(21):103184. doi: 10.3748/wjg.v31.i21.103184.
2
SIRT4 is associated with microvascular infiltration, immune cell infiltration, and epithelial mesenchymal transition in hepatocellular carcinoma.
Histol Histopathol. 2025 Apr;40(4):523-540. doi: 10.14670/HH-18-794. Epub 2024 Jul 12.
3
The current landscape of therapies for hepatocellular carcinoma.
Carcinogenesis. 2023 Oct 20;44(7):537-548. doi: 10.1093/carcin/bgad052.
4
STING pathway contributes to the prognosis of hepatocellular carcinoma and identification of prognostic gene signatures correlated to tumor microenvironment.
Cancer Cell Int. 2022 Oct 12;22(1):314. doi: 10.1186/s12935-022-02734-4.
5
High expression of CCDC6 in relation to unfavorable outcome and immune cells infiltration in hepatobiliary carcinoma.
J Cancer. 2022 Sep 21;13(12):3378-3395. doi: 10.7150/jca.76050. eCollection 2022.
6
Traditional Chinese medicine: An important source for discovering candidate agents against hepatic fibrosis.
Front Pharmacol. 2022 Aug 23;13:962525. doi: 10.3389/fphar.2022.962525. eCollection 2022.
7
Midnolin Regulates Liver Cancer Cell Growth In Vitro and In Vivo.
Cancers (Basel). 2022 Mar 10;14(6):1421. doi: 10.3390/cancers14061421.
8
Downregulation of Methionine Cycle Genes and Enriches Protein-Associated Translation Process and Worsens Hepatocellular Carcinoma Prognosis.
Int J Mol Sci. 2022 Jan 1;23(1):481. doi: 10.3390/ijms23010481.
9
The role of BCL9 genetic variation as a biomarker for hepatitis C-related hepatocellular carcinoma in Egyptian patients.
J Genet Eng Biotechnol. 2022 Jan 3;20(1):4. doi: 10.1186/s43141-021-00282-4.
10
Integrated Proteomics and Bioinformatics to Identify Potential Prognostic Biomarkers in Hepatocellular Carcinoma.
Cancer Manag Res. 2021 Mar 11;13:2307-2317. doi: 10.2147/CMAR.S291811. eCollection 2021.
本文引用的文献
1
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.
JHEP Rep. 2020 Aug 7;2(6):100167. doi: 10.1016/j.jhepr.2020.100167. eCollection 2020 Dec.
2
Liquid biopsy in the clinical management of hepatocellular carcinoma.
Gut. 2020 Nov;69(11):2025-2034. doi: 10.1136/gutjnl-2019-320282. Epub 2020 Sep 3.
3
Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect.
Cancer Manag Res. 2020 Jul 17;12:5957-5974. doi: 10.2147/CMAR.S258196. eCollection 2020.
4
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Cancers (Basel). 2020 May 31;12(6):1422. doi: 10.3390/cancers12061422.
5
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
6
Epidemiology of Hepatocellular Carcinoma.
Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288. Epub 2020 Nov 24.
7
Recent Advances in Immunotherapy for Hepatocellular Carcinoma.
Cancers (Basel). 2020 Mar 25;12(4):775. doi: 10.3390/cancers12040775.
8
Natural history of NASH and HCC.
Liver Int. 2020 Feb;40 Suppl 1:72-76. doi: 10.1111/liv.14362.
9
Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
J Hepatol. 2020 Feb;72(2):230-238. doi: 10.1016/j.jhep.2019.08.016.
10
Advances in molecular classification and precision oncology in hepatocellular carcinoma.
J Hepatol. 2020 Feb;72(2):215-229. doi: 10.1016/j.jhep.2019.08.017.
Zotero 插件